Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 207

Sort by

Sort Order Select

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Modification of post-trogocytosis effects to Enhance CAR-t cell persistence

Jianxiang Wang, Haotian Ma, Heye Yu, Shangshang Wang, Fan Ding, Haoren Wang, Wei Li, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Runxia Gu, Min Wang

Blood (2025) 146 (Supplement 1): 810.

https://doi.org/10.1182/blood-2025-810

Published: 2025

Journal Articles

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

Wenyi Lu, Bing Cao, Xin Jin, Yuanyuan Hao, Lei Zhang, Wei Cheng, Wei Li, Zhenxin Zhao, Zhoufeng Huang, Wenyan Li, Yuanbo Liu, Mingfeng Zhao, Zunmin Zhu

Blood (2025) 146 (Supplement 1): 4124.

https://doi.org/10.1182/blood-2025-4124

Published: 2025

Journal Articles

CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML

Danielle Kirkey, Corinne Summers, Katherine Tarlock, Benjamin Huang, Grace Hawkins, Nika Panahi, Melia Blankenfeld, Isabel Lira, Bruce Liu, Seungmin Shin, Rhonda Ries, Jack H. Peplinski, Simona Manni, Pamela De Falco, Biagio De Angelis, Concetta Quintarelli, Franco Locatelli, Wei Li, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 4123.

https://doi.org/10.1182/blood-2025-4123

Published: 2025

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Yaohui Huang, Siyi Chen, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2025-5382

Published: 2025

Journal Articles

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

Blood (2025) 146 (Supplement 1): 2539.

https://doi.org/10.1182/blood-2025-2539

Published: 2025

Journal Articles

Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study

Zhizhou Xia, Qifan Xu, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Wang Li

Blood (2025) 146 (Supplement 1): 60.

https://doi.org/10.1182/blood-2025-60

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Li Wang, Zhong Zheng, Ruichi Li, Pengpeng Xu, Shu Cheng, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7123.

https://doi.org/10.1182/blood-2025-7123

Published: 2025

Journal Articles

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study

Zhao Peiqi, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Huilai Zhang

Blood (2025) 146 (Supplement 1): 3595.

https://doi.org/10.1182/blood-2025-3595

Published: 2025

Journal Articles

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma

Li Wang, Jiayin He, Zhihua Yao, Hongmei Jing, Songfu Jiang, Xia Zhao, Wenrong Huang, Hongbin Lu, Zhao Peiqi, Lihong Liu, Jianzhen Shen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2025-7252

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Meng-Meng Ji, Siyuan Chen, Yige Shen, Li Wang, Shu Cheng, Pengpeng Xu, Wei Tang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2025-3732

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

FBXO3-mediated DUSP9 ubiquitination reprograms MAPK signaling to eradicate tyrosine kinase inhibitor-resistant CML stem cells

Xudong Li, Shiyu Zuo, Binglei Zhang, zhenghua huang, ruochen xu, mengjia li, Hong Huang, Yaomei Wang, Yongping Song, Baijun Fang, Bian Zhilei, Wei Li

Blood (2025) 146 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2025-3754

Published: 2025

Journal Articles

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

Rong Shen, Ling-Shuang Sheng, Zi-Xun Yan, Yu-Yue Liang, Wen Wu, Li Wang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2025-3744

Published: 2025

Journal Articles

Serum mirnas predict response to CAR-T cell therapy in large B-cell lymphoma

Ling-Shuang Sheng, Rong Shen, Zhong Zheng, Wen Wu, Li Wang, David Peng, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5307.

https://doi.org/10.1182/blood-2025-5307

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

Wei Li, Lanfang Li, Xianming Liu, Zhao Peiqi, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Huilai Zhang

Blood (2025) 146 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2025-2747

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Modification of post-trogocytosis effects to Enhance CAR-t cell persistence

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

FBXO3-mediated DUSP9 ubiquitination reprograms MAPK signaling to eradicate tyrosine kinase inhibitor-resistant CML stem cells

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

Serum mirnas predict response to CAR-T cell therapy in large B-cell lymphoma

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only